Tech Company Financing Transactions
Meditope Biosciences Funding Round
On 7/27/2013, Meditope Biosciences secured $3.6 million in Series A funding from private investors.
Transaction Overview
Company Name
Announced On
7/27/2013
Transaction Type
Venture Equity
Amount
$3,600,000
Round
Series A
Investors
Proceeds Purpose
The company will use the proceeds to accelerate development of its antibody-based cancer products.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
177 E. Colorado Blvd. 200
Pasadena, CA 91105
USA
Pasadena, CA 91105
USA
Phone
Website
Email Address
Overview
Discovered at City of Hope, Meditope's technology is capable of turning any monoclonal antibody (mAb) into a proprietary, site-specific Lego-like system that is able to attach and detach drugs to antibodies without the need for chemical conjugation.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Michael Goldberg
Chief Executive Officer
Stephanie Hsieh
Chief Financial Officer
Michael Hsieh
Chief Scientific Officer
David Stover
VP - Bus. Development
Robert McKenzie
Browse more venture capital transactions:
Prev: 7/26/2013: aPriori Technologies venture capital transaction
Next: 7/27/2013: Realm venture capital transaction
Share this article
Where The Data Comes From
We do our best to document tech company VC transactions. VC transactions on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs